Impact of %6 HES 130/0.4 and %4 Gelofusine Infusion on Kidney Function in the Living-donor Liver Transplantation

Turkiye Yuksek Ihtisas Education and Research Hospital

Status: Completed

Conditions: Patients Undergoing Liver Transplantation

Treatments: Drug: %6 HES and %4 Gelofusine

Study type: Observational

Funder types: Other

Identifiers

NCT02079350

11739 (Registry Identifier)

Details and patient eligibility

About

Although the negative impacts of colloid solutions with high molecular weight on renal functions, combination of lower molecular weight colloid varieties with crystalloid solutions and its use during intraoperative period have been subject to current research. Since the first liver transplantation, pre-or post-transplantation renal problems are still among the main causes of mortality and morbidity. The aim of the study was to evaluate the effects of fluid replacement solutions used intraoperatively on renal functions in elective living-donor liver transplantation.This study was approved by the Ethics Committee of Hospital and all patients were informed and gave written consent. Participants were patients scheduled for elective living-donor liver transplantation. Patients with normal renal function were randomly allocated to infusion with 6% HES 130/0.4 (HES Group) and 4% Gelofusine (GEL Group). Blood samples were obtained before induction of anesthesia (baseline), at the end of the operation, and postoperative days 1 and 4. Different eGFR formulas using creatinine (MDRD, CKD-EPI, and Cockraud Gault) were used to calculate estimated glomerular filtration rates.

Enrollment: 36 patients

Sex: All

Ages: 18 to 65 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

-Normal kidney function

Exclusion criteria

• anormal kidney function
• cadaveric transplantation
• emergency operation
• patients less than 18 years old

Trial design

36 participants in 2 patient groups

%4 Gelofusine

Description:

patients administered %4 Gelofusine during liver transplantation

Treatment:

Drug: %6 HES and %4 Gelofusine

%6 HES

Description:

patients administered %6 HES during liver transplantation

Treatment:

Drug: %6 HES and %4 Gelofusine